In neurology, the initial success with Aβ-targeting antibodies for AD may spur the field to advance TPD therapeutics for other neurodegeneration targets such as tau and α-synuclein (α-Syn), the major amyloid aggregate forming protein in synucleinopathies like Parkinson's disease, among others. This evidence concerns the gene MAPT and Alzheimer disease.